Torrent Pharma gets 1 USFDA observation for Bileshwarpura facility

Published On 2023-03-18 06:30 GMT   |   Update On 2023-03-18 06:30 GMT
Advertisement

Ahmedabad: Torrent Pharma has recently announced that the Company has received a Form 483 with one observation from the US Food and Drug Administration (USFDA) at the end of the pre-approval inspection at the Company's Oral-Oncology manufacturing facility at Bileshwarpura, Gujarat.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

Advertisement

The inspection was conducted from 13-Mar-23 to 17-Mar-23.

"At the end of the inspection, we have been issued a “Form 483” with 1 observation, which is procedural in nature. We will respond to the USFDA within stipulated timeline and work closely with USFDA to address the observation at the earliest," the Company informed in a BSE filing.

Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in the therapeutic segments of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology, and anti-infective segments. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma has a widespread global presence in over 40 countries.

Read also: Torrent Pharma Shelcal 500 enters market as OTC calcium supplement brand

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News